how will the mountaineer trial affect the her2-positive mcrc treatment landscape?
Published 1 year ago • 50 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:49
overview of recent changes to the treatment landscape for her2-positive crc
-
1:14
updated analysis from mountaineer: tucatinib and trastuzumab for her2-positive mcrc
-
1:11
32 month follow-up of mountaineer: tucatinib and trastuzumab in her2 mcrc
-
0:56
mountaineer results: trastuzumab and tucatinib for her2 mcrc
-
1:23
tucatinib and trastuzumab in the treatment paradigm of her2-positive mcrc
-
2:28
mountaineer: impact of genomic alterations on tucatinib plus trastuzumab activity in mcrc
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
1:08
targeting her2 in colorectal cancer
-
6:01
peaktopeak || #winningovercancer
-
6:42
tavi: all you need to know
-
5:07
options in unresectable metastatic colorectal cancer
-
0:58
mountaineer: clinical relevance of genomic profiling for tucatinib trastuzumab treatment in mcrc
-
1:19
targeted therapies for patients with her2 colorectal cancer
-
17:40
mountaineer study lead to the tucatinib/trastuzumab fda approval - in discussion w/ dr. bekaii-saab
-
4:46
mountaineer: tucatinib in combination with trastuzumab for her2-positive metastatic colorectal c...
-
1:30
how will fruquintinib fit in the colorectal cancer treatment landscape?
-
1:25
real-world treatment patterns for her2-amplified colorectal cancer
-
2:23
mountaineer-02: tucatinib in previously treated her2 gastric cancer
-
4:52
3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
-
36:12
her2-positive metastatic colorectal cancer: unraveling game-changing treatment approaches
-
1:22
influence of sidedness on prognosis and treatment in mcrc
-
1:29
future treatment landscape for colon cancer